Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 195.00 190.00 200.00 195.00 195.00 195.00 3,556 07:34:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 317

Amryt Pharma Share Discussion Threads

Showing 4576 to 4599 of 6075 messages
Chat Pages: Latest  195  194  193  192  191  190  189  188  187  186  185  184  Older
DateSubjectAuthorDiscuss
21/5/2019
09:25
Yes, I agree, diamondstar.
papillon
21/5/2019
09:07
commiseration paps...I did try and say.....
purple11
21/5/2019
08:56
good to see you back on here diamondstar, the news today in my opinion is huge and i for one did not see it coming at all. Excellent work by the board to clinch this. Finally we will be listed on the nasdaq, better appreciation of the drug sector in the states. The company did well to keep this news quite. "Enlarged group to be re-admitted to AIM and Euronext Growth on closing with a planned dual-listing on NASDAQ"
digadee
21/5/2019
08:45
Paps - I think this is the reason for the spike in Amryt share price a few days ago, rather than a share tip.
diamondstar1
21/5/2019
08:40
Yes, I did suspect that Amryt was going to inlicense Myalepta for the EU market, but they have effectively killed 2 birds with one stone with the acquisition of Aegerion -they now have a presence in North America and can market episalvan (once approved) through these channels. Having the Myalepta global market is icing on the cake. I still have very high hopes for episalvan (AP101) in EB. I know that efficacy is modest i.e. about 10% improvement in primary endpoint. But this is acceptable, especially if you are the first to market. A stroke of Irish luck here - that Zorblisa failed in Ph 3. Look what happened to GSK’s SLE drug Benlysta (belimumab), which is a success with sales increasing year-on-year. Efficacy was modest, but GSK received FDA approval in 2011, as the first drug approved for SLE in over 50 years. So, all Amryt have to do is meet the primary endpoint for EASE Ph III. Amryt do not have to show fantastic efficacy, around 20-30%. The scenario would be different, if there were other drugs already approved for EB.
diamondstar1
21/5/2019
07:42
Good to see AMYT get up to £85m upside on AP101 (given current market cap is £26m)
waterloo01
21/5/2019
07:33
Wow! Am pretty sure someone here made the connection with Myalepta, was it Diamondstar? Well called whoever it was.
bermudashorts
21/5/2019
07:17
Need to absorb. Shares suspended so time to consider but looks like a transformative move
waterloo01
21/5/2019
07:09
Didn’t see that coming!
bazworth
15/5/2019
15:24
see how TRP and i3E get along once drilling starts in a couple of months....theyre big winners pappy...tuck a few away...you could get yourself a new lawnmower for the yard when they come in.gl p.s I knew you couldn't resist a little peek at my posts...
purple11
15/5/2019
15:12
Not too long ago purple11 tipped I3E and TRP. LOL. Not set the world alight have they, purple11, since you tipped them? I3E has performed especially poorly. A right "doggy" in fact, purple11. How much are you down? That's if you ever held them! Never take any notice of pumpers and dumpers, like purple11, when they tip shares. I won't tip shares on message boards. I definitely wouldn't tip AMYT to anyone. It's a gamble I'm prepared to take, but it's definitely not for widows and orphans. It's just a risky, speculative, punt as far as I'm concerned.
papillon
15/5/2019
14:45
purple11 15 May '19 - 14:36 - 4447 of 4448 (Filtered)
papillon
15/5/2019
14:39
Back to reality. I reckon that the reason for Monday & Tuesday's rise was a tip. I remember around 20 years ago I subscribed for a short period of time in a tip sheet called The Small Company Sharewatch. I just looked on the web and I was surprised to see it still exists! hTTps://www.scsw.co.uk/ I'm not saying they tipped AMYT, but there are a lot of tip sheets out there and it's possible one of them tipped AMYT. That could explain today's fall because that often happens soon after a share has risen on a tip. Well the rise was nice as long as it lasted and the share price is still up marginally on last week.
papillon
15/5/2019
14:36
O dear pappy this doesn't look v good. hope its not a bulltrap.
purple11
15/5/2019
14:35
We seem to have gone into reverse whooooooosh!
bazworth
15/5/2019
10:47
positivityNicholas 15 May '19 - 07:50 - 4444 of 4444 (Filtered)
papillon
15/5/2019
07:50
Thanks for the insight into how to read a basic chart. You must give out more lessons and teach us more Warren Buffet. Yo
positivitynicholas
14/5/2019
20:36
A 3 year AMYT log chart. Arrow shows when bearish Death Cross occurred. free stock charts from uk.advfn.com free stock charts from uk.advfn.com
papillon
14/5/2019
17:49
I'll post a couple of charts tonight. Going by the EMA's AMYT was a sell when the 50 day EMA went below an already descending 200 day EMA (A Death Cross, a bearish signal) in October 2017 and hasn't been a buy ever since then because the 50 day EMA hasn't gone above the 200 day EMA since then (A Golden Cross is a bullish signal and occurs when the 50 day EMA rises above an already rising 200 day EMA). So as I mentioned back in October 2017 AMYT shares should have been sold then (in fact they should have been sold in September 2017 when the placing was announced). Of course I ignored my own advice! LOL.
papillon
14/5/2019
17:23
Bronxville Posts: 959 Opinion: No Opinion Price: 13.55 RE: Candid after a reread? Today 10:32 Maybe not sure.. But surely future investors in the Venn Life/Open Orphan tieup will look at Cathal Friel's double dealing at Amryt (and Fastnet) as a precedent for investing in that venture. It's only money I guess.. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Well Shareprophets (via their HotStockRockets tipping site) are evidently fans of VENN/OpenOrphan because they have tipped it. Here's what ShareProphets says today: Venn Life Sciences – transformative acquisition By HotStockRockets Venn Life Sciences (VENN) has served up 2018 results which, predictably, were a bit of a kitchen sink affair. But that is not the real news. This is the RTO of Open Orphan, which will be transformational. Ahead of that the shares will be suspended... >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> I can't post anymore because I don't subscribe to ShareProphets, or HotStockRockets. I wouldn't get too excited though because they said the same when AMYT RTO'd into FAST and that tip hasn't been profitable for those who piled in when AMYT listed (it went to the mid 30's on the morning of the first day of trading. Ouch!)
papillon
14/5/2019
10:36
Shares invariably gravitate towards their 200 day EMA. The AMYT 200 day EMA is currently at 15.1p, but falling. I wonder if the shares have been tipped?
papillon
14/5/2019
09:49
Plenty of interest volume-wise
volsung
14/5/2019
08:22
Should have said I was bored earlier, we seem to have some interest!
bazworth
14/5/2019
00:05
free stock charts from uk.advfn.com
papillon
Chat Pages: Latest  195  194  193  192  191  190  189  188  187  186  185  184  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200925 08:24:05